Calibr-Skaggs announces initial dosing of a first-in-class regenerative lung medicine in a phase 1 trial for idiopathic pulmonary fibrosis CMR316 is a once-weekly inhaled, lung-targeted drug designed to precisely expand lung stem cells and regenerate damaged lung tissue.
October 30, 2024
LA JOLLA, CA The Calibr-Skaggs Institute for Innovative Medicines, the nonprofit drug development division of Scripps Research, announced today that the first dose of a pioneering regenerative lung therapy, CMR316, has been given in a phase 1 trial assessing safety and tolerability in healthy volunteers and patients with idiopathic pulmonary fibrosis (IPF). This once-weekly, inhaled drug has potential to revolutionize treatment of lung diseases by stimulating stem cells to regenerate damaged lung tissue.
There are currently no regenerative treatments for any lung disease, including IPF, which is a deadly condition characterized by extensive tissue damage and permanent lung scarring, says Chan Beals, MD, chief medical officer of Calibr-Skaggs. Based on our encouraging preclinical data, CMR316 has the potential to halt or even reverse IPF, in addition to other severe lung conditions such as chronic obstructive pulmonary disease. This clinical milestone achieved through the collaborative bench to bedside' model of Scripps Research and Calibr-Skaggs scientists brings us closer to delivering a first-in-class medicine that could transform the lives of many people affected by debilitating lung diseases.
IPF is a severe, chronic, and progressive disease with no known cause and no cure. It affects roughly 100,000 people in the United States, drastically reducing their quality of life. With ever-increasing fibrosis in the lung over time, IPF progresses from mild shortness of breath and dry cough during activity to an inability to breathe even at rest. Difficulty breathing can lead to pulmonary hypertension and respiratory failure, preventing the brain and other organs from receiving adequate oxygen. There is no cure for IPF, aside from a lung transplant which is rarely an option, and tragically, patient survival after diagnosis is a mere 2 5 years. Available treatments, such as anti-fibrotics, can only slow disease progression and manage symptoms, highlighting the critical need for innovative new therapies. With an understanding that the lung's natural yet limited capacity to regenerate and repair is impaired in IPF, a new therapeutic strategy has emerged.
CMR316 is a first-in-class drug designed to precisely stimulate lung stem cells to regenerate lung tissue. Specifically, CMR316 targets type 2 alveolar epithelial cells (AEC2s) the stem cells in the lower airway of the lungs that are reduced in patients with IPF. Stimulating AEC2 stem cells causes them to differentiate into type 1 AEC (AEC1) cells that are crucial for gas exchange and maintaining lung stability and function. Thus, stimulating AEC2 stem cells with CMR316 has potential to repair damage caused by many lung conditions, including IPF. Furthermore, CMR316's regenerative mechanism is distinct yet complementary to that of approved anti-fibrotics, which could allow them to be combined for even greater effect.
CMR316 was discovered and developed through a partnership between Scripps Research and Calibr-Skaggs scientists, led by President and CEO Peter Schultz, PhD, and Associate Professor of Chemistry Michael Bollong, PhD, who is the Early Endowed Roon Chair for Cardiovascular Research. In April 2024, they published a study in the Proceedings of the National Academy of Sciences, which provided proof of concept for CMR316's ability to stimulate AEC2s to regenerate lung tissue in IPF and several other lung disease models.
From this foundational bench' research, the Calibr-Skaggs drug development team, led by Vice President of Pharmacology Sean Joseph, PhD, performed critical preclinical safety studies and received regulatory approval to reach the bedside' for testing CMR316 in humans.
Through careful testing of CMR316 over the last few years a huge team effort we are cautiously optimistic that the benefits and exceptional safety profile we observed preclinically will translate to patients with lung diseases, including those with IPF, says Joseph.
CMR316 is being tested at Fraunhofer ITEM in Hanover, Germany in an extensive phase 1 study in healthy volunteers (Parts 1 and 2) and patients with IPF (Part 3). The study title is A Phase 1/1b Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Nebulized CMR316 in Healthy Volunteers and Patients with Idiopathic Pulmonary Fibrosis (EU trial number: 2023-510456-23-00). The main objective of the trial is to assess the safety and tolerability of single (Part 1) and multiple inhaled doses of CMR316 in healthy volunteers (Part 2) and patients with IPF (Part 3).
This work was supported by funding from Calibr-Skaggs, with additional support from the Bachrach Family Foundation.
Calibr-Skaggs Schultz, Peter Bollong, Michael
Most recent headlines
22/12/2025
SVG New Sponsor Spotlight: Presidio's Neerav Shah on the Role of Its Captiva...
22/12/2025
Hitting the bullseye: Sky Sports readies itself for the biggest PDC World Darts ...
22/12/2025
Unique skillset: Bringing new directors to the world of darts at The Worlds with...
22/12/2025
Gravity Media prepares for a flight of fancy with the PDC World Darts Championsh...
22/12/2025
One hundred and eighty: Gravity Media on hitting the production bullseye at the ...
22/12/2025
The Famous Group's Jon Slusser on Fascinating Fans Through Immersive Content...
22/12/2025
ESPN's Meg Aronowitz on Continuing High-Quality Broadcasts of Collegiate Spo...
22/12/2025
ESPN Takes Data-Driven Storytelling to New Heights with MNF Playbook with Next ...
22/12/2025
For a decade, popular German podcast Fest & Flauschig has hosted an annual Chris...
22/12/2025
Paramount Scores Largest Share Increase Among Distributors as Paramount and CBS...
22/12/2025
New multi-year deal integrates Roku's data to fuel Nielsen's measurement suite
Roku gains access to Nielsen's streaming ratings, showing The Roku C...
22/12/2025
Share Share by:
Copy link
Facebook
X
Whatsapp
Pinterest
Flipboard...
22/12/2025
Berklee Wrapped 2025: Our Top News and Stories A look back at a year highlighted by faculty milestones, major film and television projects, Bob Dylan's ho...
22/12/2025
Partnership integrates complementary satellite data and AI analytics to enhance security, infrastructure, and environmental monitoring solutions for global cust...
22/12/2025
Workflows allow you to create a sequence of planned events which may be added to your template(s) or inserted directly into your sequential or background playli...
22/12/2025
Monday 22 December 2025
Sky extends PGA TOUR partnership until 2029, as Sky Spo...
22/12/2025
Back to All News
Global Anime Hits and New Releases Take Center Stage at Jump Festa 2026
Entertainment
22 December 2025
GlobalJapan
Link copied to clipboar...
22/12/2025
Siobh n McSweeney, Rory McIlroy, Elon Musk, Catherine Connolly, Jim Gavin, Ivan Yates and Traitor Paudie Moloney lead new characters for Callan Kicks the Year 2...
22/12/2025
Winner announced in the picturesque surroundings of Wicklow's Avondale Tower and Treetop Walk
Andrew Trimble wins the show in his first series as coach
Th...
22/12/2025
The 2025 winners have been announced today, Sunday 21 December, for Ireland's largest choral competition Choirs for Christmas hosted by RT lyric fm.
Ove...
21/12/2025
Back to All News
Legoshi and Haru's Story Reaches Its Finale: BEASTARS Fin...
21/12/2025
John Shortt named Young Sportsperson of the Year Kerry are the Team of the Year
...
20/12/2025
Atomos announced the immediate availability of a new firmware update for its Ninja TX GO and Ninja TX monitor-recorders, unlocking ProRes RAW recording from the...
20/12/2025
CJP Broadcast has completed the digitisation of the European Gymnastics tape archive, converting 328 tapes containing more than forty years of recorded material...
20/12/2025
Bitmovin, the leading provider of video streaming solutions, today announced the launch of the Stream Lab MCP Server, to give AI agents and large language model...
20/12/2025
Share Share by:
Copy link
Facebook
X
Whatsapp
Pinterest
Flipboard...
20/12/2025
Share Share by:
Copy link
Facebook
X
Whatsapp
Pinterest
Flipboard...
20/12/2025
Share Share by:
Copy link
Facebook
X
Whatsapp
Pinterest
Flipboard...
20/12/2025
Share Share by:
Copy link
Facebook
X
Whatsapp
Pinterest
Flipboard...
20/12/2025
Share Share by:
Copy link
Facebook
X
Whatsapp
Pinterest
Flipboard...
20/12/2025
Share Share by:
Copy link
Facebook
X
Whatsapp
Pinterest
Flipboard...
20/12/2025
Barack Obama Includes Laufey on His 2025 Favorite Music List The former presidents roundup of books, music, and movies includes a song from the Berklee alums ...
20/12/2025
Study reveals a key hormonal circuit in the kidneys Scripps Research scientists identify the protein that helps kidney cells regulate renin, providing foundatio...
19/12/2025
With Playout Release 2025.4, ToolsOnAir continues to push professional playout w...
19/12/2025
SVG Sit-Down: Diversified's Jared Timmins on AI for Broadcast Sports and Cre...
19/12/2025
2025 SVG Summit Audio Recap: Say What?The Audio Production and Distribution Workshop at the SVG Summit 20 took on issues including speech intelligibility, Next-...
19/12/2025
Gamified fun: Channel 5 on its NFL Big Game Night ambitions with Hungry Bear Med...
19/12/2025
College Football Playoff Preview: For ESPN, Round 1 is a Fantastic Yet Familia...
19/12/2025
AWS's Jason Dvorkin on Developing Partnerships With the NBA and PGA Tour, Em...
19/12/2025
Netflix Kicks Off Packed Sports Week with Paul-Joshua Fight Before Shifting to N...
19/12/2025
SVG New Sponsor Spotlight: Presidio's Nareev Shah on the Role of Its Captiva...
19/12/2025
Mounted to the pylon of an AH-1Z Viper helicopter, a Red Wolf vehicle successful...
19/12/2025
L3Harris technology for the SDA Tranche 3 Tracking Layer program will provide in...
19/12/2025
Partnership brings Nielsen ONE measurement activation directly into XR's adv...
19/12/2025
Share Share by:
Copy link
Facebook
X
Whatsapp
Pinterest
Flipboard...
19/12/2025
Share Share by:
Copy link
Facebook
X
Whatsapp
Pinterest
Flipboard...
19/12/2025
Berklee Announces Spring 2026 Signature Series This season's highlights include the Gospel Extravaganza, the 40th International Folk Festival, special gue...
19/12/2025
Performing arts centres across the globe have doubled down on live production infrastructure in recent years. For venues like the Queensland Performing Arts Cen...
19/12/2025
Share Share by:
Copy link
Facebook
X
Whatsapp
Pinterest
Flipboard...
Calibr-Skaggs announces initial dosing of a first-in-class regenerative lung medicine in a phase 1 trial for idiopathic pulmonary fibrosis CMR316 is a once-weekly inhaled, lung-targeted drug designed to precisely expand lung stem cells and regenerate damaged lung tissue.
